RT @mishabeltran: Great to work together with many colleagues as we outline current challenges in treating metastatic prostate cancer and s…
RT @mishabeltran: Great to work together with many colleagues as we outline current challenges in treating metastatic prostate cancer and s…
Congrats
RT @mishabeltran: Great to work together with many colleagues as we outline current challenges in treating metastatic prostate cancer and s…
Important work from a fantastic group of investigators!
RT @mishabeltran: Great to work together with many colleagues as we outline current challenges in treating metastatic prostate cancer and s…
RT @mishabeltran: Great to work together with many colleagues as we outline current challenges in treating metastatic prostate cancer and s…
RT @mishabeltran: Great to work together with many colleagues as we outline current challenges in treating metastatic prostate cancer and s…
RT @mishabeltran: Great to work together with many colleagues as we outline current challenges in treating metastatic prostate cancer and s…
RT @mishabeltran: Great to work together with many colleagues as we outline current challenges in treating metastatic prostate cancer and s…
RT @mishabeltran: Great to work together with many colleagues as we outline current challenges in treating metastatic prostate cancer and s…
RT @mishabeltran: Great to work together with many colleagues as we outline current challenges in treating metastatic prostate cancer and s…
Published today in @NatureCancer! 📚 Led by Dr. Himisha Beltran (@mishabeltran) from @DanaFarber. How precision oncology can be accelerated to inform broader genomically driven clinical decisions for advanced #ProstateCancer. https://t.co/YtnxLbvcsE https
RT @mishabeltran: Great to work together with many colleagues as we outline current challenges in treating metastatic prostate cancer and s…
RT @mishabeltran: Great to work together with many colleagues as we outline current challenges in treating metastatic prostate cancer and s…
RT @mishabeltran: Great to work together with many colleagues as we outline current challenges in treating metastatic prostate cancer and s…
RT @mishabeltran: Great to work together with many colleagues as we outline current challenges in treating metastatic prostate cancer and s…
RT @mishabeltran: Great to work together with many colleagues as we outline current challenges in treating metastatic prostate cancer and s…
RT @mishabeltran: Great to work together with many colleagues as we outline current challenges in treating metastatic prostate cancer and s…
RT @mishabeltran: Great to work together with many colleagues as we outline current challenges in treating metastatic prostate cancer and s…
RT @mishabeltran: Great to work together with many colleagues as we outline current challenges in treating metastatic prostate cancer and s…
RT @mishabeltran: Great to work together with many colleagues as we outline current challenges in treating metastatic prostate cancer and s…
RT @mishabeltran: Great to work together with many colleagues as we outline current challenges in treating metastatic prostate cancer and s…
RT @mishabeltran: Great to work together with many colleagues as we outline current challenges in treating metastatic prostate cancer and s…
RT @mishabeltran: Great to work together with many colleagues as we outline current challenges in treating metastatic prostate cancer and s…
Great to work together with many colleagues as we outline current challenges in treating metastatic prostate cancer and strategies to improve precision medicine. Here is our new Perspective @NatureCancer @quimmateo @NCIBillDahut @PCF_Science https://t.co/
Really nice comprehensive overview of precision approaches for metastatic prostate cancer by @mishabeltran @quimmateo and colleagues! Still much to do to improve therapy selection and outcomes for these patients. https://t.co/uoEJiC7e0E